Although CV mortality and all-cause mortality events were significantly reduced in the PIONEER-6 trial, the reduction in MACE did not reach statistical significance [ 13 ].
← all excerpts
Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
1
—
—